Article ; Online: The biotherapeutic
2024 Volume 16, Issue 1, Page(s) 2315631
Abstract: Immune checkpoint inhibitors (ICI) have been positioned as a standard of care for patients with advanced non-small-cell lung carcinomas (NSCLC). A pilot clinical trial has reflected optimistic association between supplementation ... ...
Abstract | Immune checkpoint inhibitors (ICI) have been positioned as a standard of care for patients with advanced non-small-cell lung carcinomas (NSCLC). A pilot clinical trial has reflected optimistic association between supplementation with |
---|---|
MeSH term(s) | Animals ; Mice ; Carcinoma, Non-Small-Cell Lung ; CD8-Positive T-Lymphocytes ; Clostridium butyricum/physiology ; Gastrointestinal Microbiome ; Interleukin-10/genetics ; Lung Neoplasms ; Nuclear Receptor Subfamily 1, Group F, Member 3 ; Programmed Cell Death 1 Receptor ; T-Lymphocytes, Regulatory |
Chemical Substances | Interleukin-10 (130068-27-8) ; Nuclear Receptor Subfamily 1, Group F, Member 3 ; Programmed Cell Death 1 Receptor |
Language | English |
Publishing date | 2024-02-22 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2575755-6 |
ISSN | 1949-0984 ; 1949-0984 |
ISSN (online) | 1949-0984 |
ISSN | 1949-0984 |
DOI | 10.1080/19490976.2024.2315631 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.